SC
VTGN icon

Steven Cohen’s VistaGen Therapeutics VTGN Stock Holding History

Steven Cohen’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-43,333
Closed -$1.66M – 1549
2019
Q1 		$1.66M Buy
+43,333
New +$1.89M 0.01% 723

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 27.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $58.9B AUM 51.73% 1-Year Est. Return

Steven Cohen's VTGN Position: Q2 2019 in Review

Steven Cohen sold out of VistaGen Therapeutics (VTGN) in Q2 2019, closing a stake of 43,333 shares — an estimated $1.66M sold.

Steven Cohen first reported a position in VTGN in Q1 2019 and held it in 1 quarter. The position peaked at $1.66M in Q1 2019. 21 funds tracked by Wall St. Rank hold VTGN as of Q2 2019.

  • Steven Cohen reported no remaining VistaGen Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Steven Cohen sold 43,333 VistaGen Therapeutics shares in Q2 2019, an estimated $1.66M.
  • Steven Cohen first reported a position in VistaGen Therapeutics in Q1 2019 and held it in 1 quarter.
  • Steven Cohen's VistaGen Therapeutics position peaked at $1.66M in Q1 2019.
  • 21 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2019.

Based on Point72 Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.